MovDisordV3, Main, Exploration, bibRecord, 002F83

Botulinum toxin treatment of lateral axial dystonia in parkinsonism

Identifieur interne : 002F83 ( Main/Exploration ); précédent : 002F82; suivant : 002F84

Botulinum toxin treatment of lateral axial dystonia in parkinsonism

Auteurs : Laura Bonanni [Italie] ; Astrid Thomas [Italie] ; Sara Varanese [Italie] ; Vincenzo Scorrano [Italie] ; Marco Onofrj [Italie]

Source :

Movement Disorders [ 0885-3185 ] ; 2007-10-31.

RBID : ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2F

Descripteurs français

Pascal (Inist)
- Bontoxilysin, Dystonie, Maladie de Parkinson, Parkinsonisme, Pathologie du système nerveux, Traitement.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Anti-Dyskinesia Agents (therapeutic use), Bontoxilysin, Botulinum Toxins (therapeutic use), Cohort Studies, Cross-Over Studies, Disability Evaluation, Double-Blind Method, Dystonia, Dystonia (drug therapy), Dystonia (etiology), Female, Humans, Male, Nervous system diseases, Pain Measurement, Parkinson Disease (complications), Parkinson disease, Parkinson's disease., Parkinsonism, Treatment, botulinum toxin, lateral axial dystonia, parkinsonism.
MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- complications : Parkinson Disease.
- drug therapy : Dystonia.
- etiology : Dystonia.
- Aged, Aged, 80 and over, Cohort Studies, Cross-Over Studies, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Pain Measurement.

Abstract

Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society

Url:

https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/pdf

DOI: 10.1002/mds.21694

Affiliations:

Italie

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title>
<author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
</author>
<author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
</author>
<author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
</author>
<author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
</author>
<author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2F</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21694</idno>
<idno type="url">https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001151</idno>
<idno type="wicri:Area/Istex/Curation">001151</idno>
<idno type="wicri:Area/Istex/Checkpoint">001A91</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Bonanni L:botulinum:toxin:treatment</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17685467</idno>
<idno type="wicri:Area/PubMed/Corpus">002566</idno>
<idno type="wicri:Area/PubMed/Curation">002566</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002940</idno>
<idno type="wicri:Area/Ncbi/Merge">001D93</idno>
<idno type="wicri:Area/Ncbi/Curation">001D93</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001D93</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Bonanni L:botulinum:toxin:treatment</idno>
<idno type="wicri:Area/Main/Merge">003F05</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0069702</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001473</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001846</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001768</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Bonanni L:botulinum:toxin:treatment</idno>
<idno type="wicri:Area/Main/Merge">004358</idno>
<idno type="wicri:Area/Main/Curation">002F83</idno>
<idno type="wicri:Area/Main/Exploration">002F83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title>
<author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara</wicri:regionArea>
<wicri:noRegion>University G. D'Annunzio of Chieti‐Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara</wicri:regionArea>
<wicri:noRegion>University G. D'Annunzio of Chieti‐Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara</wicri:regionArea>
<wicri:noRegion>University G. D'Annunzio of Chieti‐Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara</wicri:regionArea>
<wicri:noRegion>University G. D'Annunzio of Chieti‐Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara</wicri:regionArea>
<wicri:noRegion>University G. D'Annunzio of Chieti‐Pescara</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara</wicri:regionArea>
<wicri:noRegion>Pescara</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-10-31">2007-10-31</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">14</biblScope>
<biblScope unit="page" from="2097">2097</biblScope>
<biblScope unit="page" to="2103">2103</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3356E99C7EA40BB813365608ED79D30B616D8E2F</idno>
<idno type="DOI">10.1002/mds.21694</idno>
<idno type="ArticleID">MDS21694</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Dystonia</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (etiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Pain Measurement</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease.</term>
<term>Parkinsonism</term>
<term>Treatment</term>
<term>botulinum toxin</term>
<term>lateral axial dystonia</term>
<term>parkinsonism</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dystonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cohort Studies</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Pain Measurement</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Dystonie</term>
<term>Maladie de Parkinson</term>
<term>Parkinsonisme</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
</noRegion>
<name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name>
<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>
<name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name>
<name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name>
<name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
<name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2F
   |texte=   Botulinum toxin treatment of lateral axial dystonia in parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Botulinum toxin treatment of lateral axial dystonia in parkinsonism

Botulinum toxin treatment of lateral axial dystonia in parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.